Search bioRxiv⌕ Search

Biology subjects

Nass, T.

Publications and source records attributed to Nass, T..

2 recordsLinked to original sources

Field-isolate recombinant tick-borne encephalitis viruses define reporter-stability guidelines for antiviral screening in flaviviruses

As arthropod-borne viruses continue to threaten populations globally, there is a pressing need for experimental systems that enable rapid antiviral discovery. Reverse-genetics platforms producing recombinant reporter orthoflaviviruses have been developed to address this gap. Here, we present two new recombinant tick-borne encephalitis viruses (TBEVrec) generated on a European-subtype Haselmuehl Tiho1 isolate backbone. A reporter gene, either eGFP or Nluc, was inserted in the capsid-coding region of the genome downstream of the capsid RNA regulatory signal and separated from the complete viral polyprotein by a 2A self-cleaving peptide. TBEVrec was better rescued using the circular polymerase extension reaction (CPER) than with the infectious subgenomic amplicon (ISA) method. TBEVrec replicated efficiently in relevant human cell lines, with comparable replication to wild-type TBEV in a neuronal cell line and moderately reduced titers and RNA levels in immune-derived cell lines. Using either eGFP or Nluc, we illustrate how TBEVrec enabled high-content RNAi screening, highlighting Nucleolin and PRKD1 as potential TBEV host factors, and drug testing on a benchtop plate reader. Nanopore sequencing of the eGFP insert revealed that the reporter is excised without affecting flanking regions. Comparative analysis of eGFP and Nluc further shows that this instability is time- and cell type-dependent, and that Nluc is comparatively more stable. From these observations, we outline safeguards and design principles that are broadly applicable both to the rescue of existing constructs and to the design of future recombinant reporter virus platforms.

microbiology↗

Vehiculation and functional delivery of lipophilic therapeutics and antibiotics via pulmonary surfactant in a lung-on-chip model

Pulmonary surfactant forms a dynamic proteolipid thin-film at the alveolar air-liquid interface. It is both a barrier to but also a "last-mile" carrier for inhaled particulate matter to the distal lung. The role of vehiculation in pulmonary delivery of inhaled therapeutics remains poorly understood, as it cannot be easily studied in animal models, and is not recapitulated in liquid cell culture. Here we adapted a thin-film bridge (TFB) delivery method from vehiculation experiments in acellular models to a lung-on-chip (LoC) platform under breathing-like stretch. Using confocal live-imaging, we demonstrate vehiculation and cellular uptake of fluorescently-labelled cargoes such as Tacrolimus or Beclomethasone. We systematically compared TFB vehiculation to existing in vitro delivery approaches. TFB vehiculation promoted sustained retention of functionally effective Tacrolimus, strong co-localization with surfactant lipids, and accumulation in macrophages in human LoCs reconstituted with in vitro-differentiated alveolar macrophage-like cells. This contrasted with the unphysiological dominant uptake of formulations in liquid by alveolar epithelial cells. Finally, in proof-of-concept experiments, TFB-vehiculated bedaquiline effectively supressed subsequent growth of Mycobacterium tuberculosis in a prophylactic manner. Overall, our work demonstrates an approach for studying drug vehiculation in models of the alveolar interface in vitro, and the feasibility of surfactant-containing therapeutic formulations for direct and effective pulmonary delivery.

bioengineering↗